<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.105082</article-id><article-id pub-id-type="publisher-id">TCM-44979</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210500000_19733400.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  基于网络药理学探讨芪–归药对防治骨髓抑制毒性的作用机制
  Potential Mechanisms of Huangqi-Danggui Herb Pairs in the Treatment of Myelosuppression Based on Network Pharmacology
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>雪阳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>梦丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>妍昕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>娜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>原</surname><given-names>媛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>宇飞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>一乔</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>新乡医学院，河南 新乡</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>31</day><month>08</month><year>2021</year></pub-date><volume>10</volume><issue>05</issue><fpage>609</fpage><lpage>619</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：利用网络药理学研究策略，结合中药对机体代谢的调控作用，探讨黄芪–当归药对防治化疗药物骨髓抑制毒性的直接作用及间接调控机制。方法：通过网络数据库，筛选得到芪–归药对中活性成分可直接作用的病理靶点，构建“活性成分–蛋白靶点–病理机制”直接交互网络；同时，以中药对体内代谢调控及骨髓抑制毒性发病机制为基础，从中药影响内源性物质代谢角度，筛选出芪–归药对可间接调控的作用靶点。利用分子对接模拟实验，验证所筛选关键靶蛋白与黄芪与当归中有效成分的结合活性。结果：从数据库中共筛选得到芪–归药对中154个潜在活性成分和11个核心靶点，主要涉及细胞表面离子通道、胞内蛋白激酶、p53等信号通路；同时，代谢通路富集分析表明，芪–归药对机体酮体代谢具有调控作用，亦可作为防治骨髓抑制毒性的潜在机制。分子对接结果显示，所筛选关键靶蛋白与芪–归药对中有效成分具有良好的结合活性。结论：芪–归药对防治化疗骨髓抑制毒性具有多成分、多靶点、代谢复杂、药效输出广泛、多途径协同增效的作用特点，并可能通过调控机体代谢进而发挥防治功效。该研究为后续道地药材资源的开发、芪–归药对防治骨髓抑制的药效物质基础及作用机制研究提供了理论依据。
  Object: Network pharmacology research strategies combined with Traditional Chinese Medicine metabolic regulation theories were used to study direct and indirect mechanisms of Hua-ngqi-Danggui herb pairs (HD) for the prevention and treatment of chemotherapeutic myelosup-pression. Methods: Chemical components and related targets of HD were searched using network database. Combined with myelosuppression related targets, “chemical-targets-disease” network was established. Meanwhile, related targets in metabolism which HD may regulate were also screened out. The molecular docking simulation experiment was used to verify the binding activity of the screened key target proteins to the active components. Results: 154 potential active components and 11 core targets were screened out by topology analysis. Meanwhile, metabolic pathways enrichment analysis showed that HD can regulate ketone body metabolism. The results showed that cell surface channels, cytosol protein kinase activity, p53 class mediator signal transduction pathway and ketone body metabolism may play important roles for the prevention and treatment of myelosuppression by HD. Conclusion: This study indicated that the prevention and treatment of myelosuppression by HD were a synergetic effect with multi-components, multi-targets and ketone body metabolism may also play crucial parts. The direct and indirect mechanisms we revealed may provide the theoretical basis for pharmacodynamic materials and functional mechanisms studies of HD.
 
</p></abstract><kwd-group><kwd>芪–归药对，骨髓抑制，网络药理学，酮体代谢, Huangqi-Danggui Herb Pairs</kwd><kwd> Myelosuppression</kwd><kwd> Network Pharmacology</kwd><kwd> Ketone Body Metabolism</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：利用网络药理学研究策略，结合中药对机体代谢的调控作用，探讨黄芪–当归药对防治化疗药物骨髓抑制毒性的直接作用及间接调控机制。方法：通过网络数据库，筛选得到芪–归药对中活性成分可直接作用的病理靶点，构建“活性成分–蛋白靶点–病理机制”直接交互网络；同时，以中药对体内代谢调控及骨髓抑制毒性发病机制为基础，从中药影响内源性物质代谢角度，筛选出芪–归药对可间接调控的作用靶点。利用分子对接模拟实验，验证所筛选关键靶蛋白与黄芪与当归中有效成分的结合活性。结果：从数据库中共筛选得到芪–归药对中154个潜在活性成分和11个核心靶点，主要涉及细胞表面离子通道、胞内蛋白激酶、p53等信号通路；同时，代谢通路富集分析表明，芪–归药对机体酮体代谢具有调控作用，亦可作为防治骨髓抑制毒性的潜在机制。分子对接结果显示，所筛选关键靶蛋白与芪–归药对中有效成分具有良好的结合活性。结论：芪–归药对防治化疗骨髓抑制毒性具有多成分、多靶点、代谢复杂、药效输出广泛、多途径协同增效的作用特点，并可能通过调控机体代谢进而发挥防治功效。该研究为后续道地药材资源的开发、芪–归药对防治骨髓抑制的药效物质基础及作用机制研究提供了理论依据。</p></sec><sec id="s2"><title>关键词</title><p>芪–归药对，骨髓抑制，网络药理学，酮体代谢</p></sec><sec id="s3"><title>Potential Mechanisms of Huangqi-Danggui Herb Pairs in the Treatment of Myelosuppression Based on Network Pharmacology</title><p>Xueyang Wang, Mengli Zhang, Yanxi Li, Na Li, Yuan Yuan, Yufei Liu, Yiqiao Gao<sup>*</sup></p><p>Xinxiang Medical University, Xinxiang Henan</p><p><img src="//html.hanspub.org/file/2-2270727x5_hanspub.png?20210903082557107" /></p><p>Received: Jul. 12<sup>th</sup>, 2021; accepted: Aug. 26<sup>th</sup>, 2021; published: Sep. 2<sup>nd</sup>, 2021</p><p><img src="//html.hanspub.org/file/2-2270727x6_hanspub.png?20210903082557107" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Object: Network pharmacology research strategies combined with Traditional Chinese Medicine metabolic regulation theories were used to study direct and indirect mechanisms of Huangqi-Danggui herb pairs (HD) for the prevention and treatment of chemotherapeutic myelosuppression. Methods: Chemical components and related targets of HD were searched using network database. Combined with myelosuppression related targets, “chemical-targets-disease” network was established. Meanwhile, related targets in metabolism which HD may regulate were also screened out. The molecular docking simulation experiment was used to verify the binding activity of the screened key target proteins to the active components. Results: 154 potential active components and 11 core targets were screened out by topology analysis. Meanwhile, metabolic pathways enrichment analysis showed that HD can regulate ketone body metabolism. The results showed that cell surface channels, cytosol protein kinase activity, p53 class mediator signal transduction pathway and ketone body metabolism may play important roles for the prevention and treatment of myelosuppression by HD. Conclusion: This study indicated that the prevention and treatment of myelosuppression by HD were a synergetic effect with multi-components, multi-targets and ketone body metabolism may also play crucial parts. The direct and indirect mechanisms we revealed may provide the theoretical basis for pharmacodynamic materials and functional mechanisms studies of HD.</p><p>Keywords:Huangqi-Danggui Herb Pairs, Myelosuppression, Network Pharmacology, Ketone Body Metabolism</p><disp-formula id="hanspub.44979-formula10"><graphic xlink:href="//html.hanspub.org/file/2-2270727x7_hanspub.png?20210903082557107"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-2270727x8_hanspub.png?20210903082557107" /> <img src="//html.hanspub.org/file/2-2270727x9_hanspub.png?20210903082557107" /></p></sec><sec id="s5"><title>1. 引言</title><p>黄芪(Astragali radix)和当归(Angelicae sinensis radix)均为甘肃省道地药材 [<xref ref-type="bibr" rid="hanspub.44979-ref1">1</xref>]。黄芪补脾肺之气，当归补血活血，二者合用，气血双补 [<xref ref-type="bibr" rid="hanspub.44979-ref2">2</xref>]。化疗是临床用于治疗恶性肿瘤的常用手段，但大多数化疗药物伴随有骨髓抑制毒性，进而导致治疗方案的中断，甚至诱发严重性感染 [<xref ref-type="bibr" rid="hanspub.44979-ref3">3</xref>]。中医理论认为，化疗所致骨髓抑制属于“虚劳、血虚”症候范畴，按照“虚则补之、损则益之”的施治观点，芪–归药对作为补气生血方剂中的最佳配伍，在骨髓抑制的防治中应用广泛，且疗效已有确切临床报道 [<xref ref-type="bibr" rid="hanspub.44979-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.44979-ref5">5</xref>]。</p><p>目前，芪–归药对防治骨髓抑制的机制研究已取得一定进展 [<xref ref-type="bibr" rid="hanspub.44979-ref6">6</xref>]，如上调Notch信号通路，激活Notch受体及其配体表达等，芪–归药对治疗贫血等血液疾病的网络药理学也已有报道 [<xref ref-type="bibr" rid="hanspub.44979-ref7">7</xref>]，但考虑到骨髓–血屏障的存在、骨髓抑制病因的复杂性及中药对机体代谢稳态的调控作用 [<xref ref-type="bibr" rid="hanspub.44979-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.44979-ref9">9</xref>]，除以骨髓抑制毒性病理机制靶点作为直接筛选指标外，也需从中药对机体代谢调控角度出发，全面分析芪–归药对防治骨髓抑制的综合机制 [<xref ref-type="bibr" rid="hanspub.44979-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44979-ref11">11</xref>]。本研究旨在利用网络药理学策略，结合中药对机体代谢的调控作用，从中药直接作用和间接调控两个角度，探讨芪–归药对防治骨髓抑制药效机制，以期从网络药理学角度实现对现有研究报道的相互印证，同时挖掘其他尚未报道潜在药效靶点，为化疗所致骨髓抑制毒性的中药防治研究及甘肃道地药材黄芪、当归的临床应用提供有益指导。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 网络数据库及软件</title><p>TCMSP (http://lsp.nwsuaf.edu.cn/tcmsp.php/)；TCMID (http://www.megabionet.org/tcmid/)；TDT (http://tcm.cmu.edu.tw/zh-tw/)；Drugbank (https://www.drugbank.ca/)；STITCH (http://stitch.embl.de/cgi/)；PharmGKB (https://www.pharmgkb.org/)；OMIM (http://www.omim.org/)；TTD (http://bidd.nus.edu.sg/group/cjttd/)；GAD (https://geneticassociationdb.nih.gov/)；UniProt (http://www.uniprot.org/)；STRING (https://string-db.org/)；DAVID (https://david.ncifcrf.gov)；KEGG (http://www.genome.jp/kegg/)；BATMAN-TCM (http://bionet.ncpsb.org/batman-tcm/)；RCSBPDB (http://www.rcsb.org/)；Cytoscape version 3.7.2、R version 3.6.1、Autodock1.5.6、ChemDraw 18.0软件。</p></sec><sec id="s6_2"><title>2.2. 芪–归药对活性成分及作用靶点筛选</title><p>采用中药资源在线数据库TCMSP、TCMID及TDT，获取黄芪及当归所含化学成分。以五倍率法则(Lipinski’s rule)为标准 [<xref ref-type="bibr" rid="hanspub.44979-ref12">12</xref>]，结合文献报道，遴选芪–归药对中潜在活性成分。随后，利用TCMSP、Drugbank及STITCH数据库，检索并汇总得到潜在活性成分的作用靶点。</p></sec><sec id="s6_3"><title>2.3. 骨髓抑制病理靶点的筛选</title><p>于PharmGKB、OMIM、TTD和GAD数据库中检索并汇总得到与骨髓抑制病理机制相关的靶点数据，进一步利用UniProt数据库，将以上所得靶点均校正为人类蛋白UniProt ID，以便于后续统一分析处理。</p></sec><sec id="s6_4"><title>2.4. “活性成分–蛋白靶点–病理机制”直接交互网络的构建与分析</title><p>将中药活性成分作用靶标与骨髓抑制病理靶标进行匹配，得到芪–归药对活性成分防治骨髓抑制的潜在作用靶点。将相关成分及靶点导入Cystoscope version 3.7.2软件，构建“活性成分–蛋白靶点–病理机制”直接交互网络并进行拓扑分析。以节点(Node)间的拓扑参数“连接度(Degree)”、“近中心性(Closeness Centrality, CC)”和“介中心性(Betweenness Centrality, BC)”为指标，进一步筛选核心靶点，并利用STRING在线工作站分析核心靶点蛋白的互作关系。</p></sec><sec id="s6_5"><title>2.5. 核心靶点的富集分析</title><p>利用DAVID 6.8数据库对所筛核心靶点进行GO (Geno Ontology)富集分析和KEGG通路注释分析，分别从分子功能(Molecular Function, MF)、生物学过程(Biological Process, BP)、细胞位点(Cellular Component, CC)及KEGG代谢通路四个角度探讨芪–归药对防治骨髓抑制的直接作用机制。</p></sec><sec id="s6_6"><title>2.6. 芪–归药对影响内源性代谢通路</title><p>利用BATMAN-TCM及KEGG数据库，筛选并汇总芪–归药对中的活性成分对机体内源性代谢通路的干预作用。结合骨髓抑制毒性病理机制及内源性代谢物的分子生物学功能，探讨芪–归药对通过干预内源性物质代谢进而发挥防治功效的间接药效机制。</p></sec><sec id="s6_7"><title>2.7. 核心靶点的分子对接模拟验证</title><p>利用RCSBPDB数据库及ChemDraw 18.0软件，分别获得靶点蛋白及药对中活性成分的晶体结构，通过Autodock1.5.6软件计算靶点蛋白与活性成分间的最低结合能，并将分子对接模拟验证结果进行可视化呈现。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 药物靶点及疾病靶点的筛选</title><p>采用1.2项下方法，分别对黄芪和当归中的潜在活性成分及作用靶点进行筛选。从黄芪中共筛选得到49个活性成分，主要包括黄酮类(如山奈酚、槲皮素)、黄芪苷类(如黄芪甲苷)、有机酸类(如香草酸)等，共涉及305个靶点；从当归中共筛选得到105个活性成分，主要包括挥发油类(如异丁香酚)、内酯类(如藁本内酯)、有机酸类(如阿魏酸)等，共涉及176个靶点。</p><p>采用1.3项下方法，在疾病数据库中共检索得到254个骨髓抑制相关靶点。将芪–归药对靶点与骨髓抑制疾病靶点进行对比(图1)，重叠靶点共51个，可作为芪–归药对直接发挥防治功效的潜在靶点。其中，黄芪和当归共同作用的靶点共17个，说明二者防治骨髓抑制可能存在叠加和协同增效作用。</p><p>图1. 药物靶点与疾病靶点韦恩图</p></sec><sec id="s7_2"><title>3.2. “活性成分–蛋白靶点–病理机制”直接交互网络的建立</title><p>将芪–归药对活性成分及骨髓抑制相关蛋白靶点导入Cytoscape软件进行可视化分析，构建“活性成分–蛋白靶点–病理机制”直接交互网络(图2)。图中椭圆节点代表芪–归药对中活性成分(PubChem CID)，三角形节点代表骨髓抑制相关靶点(UniProt Gene Names)。以“Degree”表示网络图中各节点间相连路线的个数，发现芪–归药对中均有两个或以上活性成分作用于骨髓抑制相关靶点，体现出中药药对“多成分、多靶点、协同增效”的作用特点。</p><p>图2. “活性成分–蛋白靶点–骨髓抑制”直接交互网络</p><p>为进一步筛选芪–归药对防治骨髓抑制核心蛋白靶点，对所建立交互网络进行拓扑分析，得到三个拓扑参数Degree、BC和CC的中位数分别为3、0.00155和0.40613。以Degree值大于其中位数2倍、BC值和CC值大于各自中位数为标准 [<xref ref-type="bibr" rid="hanspub.44979-ref13">13</xref>]，筛选出11个核心蛋白靶点(表1)。核心蛋白靶点间的互作关系如图3所示，说明核心蛋白靶点间具有一定的相关性。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The core target for Huangqi-Danggui herb pairs against myelosuppressio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >序号</th><th align="center" valign="middle" >靶点基因</th><th align="center" valign="middle" >蛋白名称</th><th align="center" valign="middle" >Degree</th><th align="center" valign="middle" >BC</th><th align="center" valign="middle" >CC</th><th align="center" valign="middle" >UniProt ID</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >ACHE</td><td align="center" valign="middle" >Acetylcholinesterase</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0.01785</td><td align="center" valign="middle" >0.42915</td><td align="center" valign="middle" >P22303</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >BAX</td><td align="center" valign="middle" >Apoptosis regulator BAX</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >0.00785</td><td align="center" valign="middle" >0.41890</td><td align="center" valign="middle" >Q07812</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >BCL2</td><td align="center" valign="middle" >Apoptosis regulator Bcl-2</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >0.00691</td><td align="center" valign="middle" >0.41569</td><td align="center" valign="middle" >P10415</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >CDK2</td><td align="center" valign="middle" >Cyclin-dependent kinase 2</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >0.01545</td><td align="center" valign="middle" >0.43265</td><td align="center" valign="middle" >P24941</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >CHEK1</td><td align="center" valign="middle" >Serine/threonine-protein kinase Chk1</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0.01199</td><td align="center" valign="middle" >0.42915</td><td align="center" valign="middle" >O14757</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >F2</td><td align="center" valign="middle" >Prothrombin</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >0.03372</td><td align="center" valign="middle" >0.44352</td><td align="center" valign="middle" >P00734</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >MAPK14</td><td align="center" valign="middle" >Mitogen-activated protein kinase 14</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >0.00983</td><td align="center" valign="middle" >0.42570</td><td align="center" valign="middle" >Q16539</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >NOS2</td><td align="center" valign="middle" >Nitric oxide synthase, inducible</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >0.02806</td><td align="center" valign="middle" >0.44726</td><td align="center" valign="middle" >P35228</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >PRSS3</td><td align="center" valign="middle" >Trypsin-3</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0.02458</td><td align="center" valign="middle" >0.42570</td><td align="center" valign="middle" >P35030</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >SLC6A2</td><td align="center" valign="middle" >Sodium-dependent noradrenaline transporter</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >0.08858</td><td align="center" valign="middle" >0.47964</td><td align="center" valign="middle" >P23975</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >TNF</td><td align="center" valign="middle" >Tumor necrosis factor</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >0.00493</td><td align="center" valign="middle" >0.41569</td><td align="center" valign="middle" >P01375</td></tr></tbody></table></table-wrap><p>表1. 芪–归药对防治骨髓抑制核心靶点</p><p>图3. 核心蛋白靶点互作关系</p></sec><sec id="s7_3"><title>3.3. 核心靶点的GO富集分析</title><p>利用DAVID数据库，以错误发现率(False Discovery Rate, FDR)校正P值小于0.05为筛选标准，对核心蛋白靶点基因所涉及分子功能(MF)、细胞位点(CC)和生物学过程(BP)进行GO富集分析及排序，结果如图4所示。芪–归药对防治骨髓抑制的核心靶点主要分布于细胞表面(Cell surface)、细胞核(Nucleus)及细胞质(Cytosol)，具有调控离子通道活性(Channel activity)、蛋白激酶活性(Protein kinase activity)等分子功能。所涉及生物学过程主要包括p53介导的信号传导(Regulation of signal transduction by p53 class mediator)、死亡受体介导的细胞凋亡(Extrinsic apoptotic signaling pathway via death domain receptors)和细胞质内钙离子的释放调控(Positive regulation of release of sequestered calcium ion into cytosol)等通路。</p></sec><sec id="s7_4"><title>3.4. 核心靶点的KEGG富集分析</title><p>通过DAVID数据库对核心靶点进行KEGG富集分析，得到芪–归药对防治骨髓抑制的潜在作用通路(图5)。结果表明，芪–归药对可能通过调控p53、AGE-RAGE和鞘脂代谢等信号通路来直接发挥对骨髓抑制的防治作用，其中，p53信号通路具有最高的相关性，所涉及的核心靶点包括CDK2、BAX和Bcl2等。</p></sec><sec id="s7_5"><title>3.5. 芪–归药对对机体代谢的调控</title><p>利用BATMAN-TCM数据库对芪–归药对中活性成分所调控的代谢通路进行KEGG富集分析，结果表明，芪–归药对主要通过作用于乙酰辅酶A合成酶、乙酰辅酶A乙酰转移酶、3-羟基丁酸脱氢酶等代谢酶影响机体能量代谢和酮体代谢，涉及三羧酸循环、糖酵解、脂肪酸降解、生酮氨基酸代谢、酮体合成等代谢途径(图6)。</p></sec><sec id="s7_6"><title>3.6. 分子对接模拟验证</title><p>选择KEGG富集分析中与芪–归药对防治骨髓抑制相关性最高的p53通路中核心靶点Bcl2、芪–归药对对机体代谢调控的关键酶BHD2 (β-羟丁酸脱氢酶)为靶点蛋白，芪–归药对中代表性活性成分黄芪甲苷和阿魏酸为活性分子，利用Autodock1.5.6软件计算靶点蛋白与活性分子间的最低结合能，结果显示(图7)，靶点蛋白与活性分子的最低结合能均位于 −5.99 kal∙mol<sup>−1</sup>至 −4.76 kal∙mol<sup>−1</sup>之间，说明二者可能具有较好的结合活性，靶点蛋白与活性分子之间能够通过氢键等分子间作用力形成稳定构象 [<xref ref-type="bibr" rid="hanspub.44979-ref14">14</xref>]。</p><p>图4. 核心靶点GO富集分析</p><p>图5. 核心靶点KEGG富集分析</p><p>图6. 芪–归药对对内源性代谢通路中代谢酶及代谢物的影响</p><p>图7. 靶点蛋白与活性分子的模拟对接验证：(a) 黄芪甲苷与Bcl2 (−4.76 kal∙mol<sup>−1</sup>)；(b) 黄芪甲苷与BHD2 (−4.95 kal∙mol<sup>−1</sup>)；(c) 阿魏酸与Bcl2 (−5.01 kal∙mol<sup>−1</sup>)；(d) 阿魏酸与BHD2 (−5.99 kal∙mol<sup>−1</sup>)；(蓝色：靶点蛋白；绿色：活性分子；黄色：氢键；红色：结合位点)</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>中药复方具有“多成分、多靶点、代谢复杂、药效输出广泛、多途径协同增效”的作用特点，其活性成分既可直接作用于疾病靶蛋白发挥药效，又可通过干预内源性物质代谢发挥间接治疗作用。因此，仅针对单一成分、单一靶点或单一途径的研究思路很难实现对中药复方整体作用机制和配伍机制的全面分析。网络药理学强调疾病的发生涉及多基因、多通路的分子网络相互作用，代谢通路网络将机体内源性代谢物、代谢酶及其生物学功能相关联。将网络药理学和代谢通路网络结合，实现中药活性成分网络、病理机制网络及内源性代谢网络的桥接，为现代中药活性成分发现、药效作用机制、组方开发及优化等研究提供了新的思路与工具。</p><p>目前，对芪–归药对治疗贫血等血液疾病的网络药理学及作用通路研究已有报道，但化疗所致骨髓抑制毒性病因复杂，且中药对机体代谢的调控作用是其发挥防治功效的潜在机制 [<xref ref-type="bibr" rid="hanspub.44979-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44979-ref11">11</xref>]，因此本研究旨在利用网络药理学策略，结合中药对机体代谢的调控作用，从中药直接作用和间接调控两个角度，探讨芪–归药对防治骨髓抑制药效机制，实现对已有研究报道的相互印证，同时挖掘其他潜在药效靶点。</p><p>本研究首先采用网络药理学策略，筛选芪–归药对防治骨髓抑制毒性的直接作用靶点。通过构建“中药活性成分–蛋白靶点–病理机制”直接交互网络，筛选得到芪–归药对中154个潜在活性成分和373个蛋白靶点，其中51个与骨髓抑制病理机制靶点重合。进一步利用拓扑分析，从中遴选得到11个核心蛋白靶点。</p><p>GO富集分析发现，细胞表面、细胞质、细胞核的离子通道和激酶活性与核心蛋白靶点的细胞位点及分子功能密切相关。研究表明，免疫细胞通过表面离子通道调节胞质内钙离子含量；同时，胞质内钙离子含量能够通过影响蛋白激酶及细胞核表面相关蛋白来干预IL-2的表达，实现对免疫细胞激活、分化和增殖的调控 [<xref ref-type="bibr" rid="hanspub.44979-ref15">15</xref>]。芪–归药对中活性成分黄芪甲苷已被证实能够提高血清中IL-2的含量 [<xref ref-type="bibr" rid="hanspub.44979-ref16">16</xref>]，为本研究网络药理学分析结果提供了实验证据，即芪-归药对中活性成分可能作用于上述离子通道及蛋白激酶，回调化疗药物造成的免疫细胞大量减少，发挥对骨髓抑制的防治作用。</p><p>核心靶点的BP及KEGG富集分析结果均表明，p53介导的信号通路可能是芪–归药对防治骨髓抑制的关键通路。p53信号通路已被证实是诱发造血干细胞不规则凋亡及骨髓抑制的关键通路 [<xref ref-type="bibr" rid="hanspub.44979-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.44979-ref18">18</xref>]，对p53信号通路中Bcl2的上调可用于预防化疗所致的骨髓抑制 [<xref ref-type="bibr" rid="hanspub.44979-ref19">19</xref>]。已有研究发现，芪–归药对能够促进造血干细胞中Bcl2的表达 [<xref ref-type="bibr" rid="hanspub.44979-ref20">20</xref>]，证明了本研究网络药理学筛选及分子对接结果的准确性。然而，芪–归药对作用于p53通路的具体药效物质基础以及对通路中除Bcl2之外其它关键靶点的调节作用机制仍亟待进一步的研究。</p><p>内源性代谢物可作为功能性配体，影响机体内环境稳态、药物代谢或疾病进程。富集分析表明，芪–归药对可通过影响脂肪酸降解、生酮氨基酸代谢、酮体合成等途径中的代谢酶进而调控机体酮体水平。β-羟基丁酸作为机体含量最高的酮体类物质，可作为内源性信号分子，通过抑制组蛋白去乙酰化酶(histone deacetylase, HDAC)增强抗氧化应激因子FOXO3A和MT2基因的转录，降低机体氧化应激水平 [<xref ref-type="bibr" rid="hanspub.44979-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.44979-ref22">22</xref>]。化疗药物可引起机体氧化应激失衡，进而导致造血干细胞衰老及自我更新能力的受损 [<xref ref-type="bibr" rid="hanspub.44979-ref23">23</xref>]，已被证实是化疗致骨髓抑制毒性产生的关键机制 [<xref ref-type="bibr" rid="hanspub.44979-ref9">9</xref>]。Foxo3、mTOR等多种信号分子均可通过调控机体氧化应激水平进而影响骨髓造血功能，具有重要的临床应用前景 [<xref ref-type="bibr" rid="hanspub.44979-ref24">24</xref>]。结合富集分析及分子对接结果，推测芪–归药对可能通过调控酮体代谢，提高机体β-羟基丁酸表达水平，抑制HDAC活力，增强FOXO3A和MT2基因的转录，降低机体氧化应激水平，进而发挥对骨髓抑制毒性的防治功效。以上分析结果与近期研究所提出的猜想相吻合 [<xref ref-type="bibr" rid="hanspub.44979-ref6">6</xref>]。</p></sec><sec id="s9"><title>5. 结论</title><p>综上，本研究利用网络药理学研究策略，结合中药对机体代谢的调控作用，探讨芪–归药对防治化疗药物骨髓抑制毒性的潜在作用机制。一方面，通过网络数据库，筛选得到芪–归药对中活性成分可直接作用的骨髓抑制病理靶点，构建“活性成分–蛋白靶点–病理机制”直接交互网络；另一方面，从中药影响内源性物质代谢角度，筛选出芪–归药对可间接调控的作用靶点。本研究初步揭示了芪–归药对防治化疗骨髓抑制毒性具有多成分、多靶点、代谢复杂、药效输出广泛、多途径协同增效的作用特点，并可能通过调控机体代谢进而发挥防治功效，为后续道地药材资源的开发、芪–归药对防治骨髓抑制的药效物质基础及作用机制研究提供了理论依据。</p></sec><sec id="s10"><title>基金项目</title><p>新乡医学院省级大学生创新创业训练计划项目(S202010472027，S202010472044，210710472018)。</p></sec><sec id="s11"><title>文章引用</title><p>王雪阳,张梦丽,李妍昕,李 娜,原 媛,刘宇飞,高一乔. 基于网络药理学探讨芪–归药对防治骨髓抑制毒性的作用机制Potential Mechanisms of Huangqi-Danggui Herb Pairs in the Treatment of Myelosuppression Based on Network Pharmacology[J]. 中医学, 2021, 10(05): 609-619. https://doi.org/10.12677/TCM.2021.105082</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44979-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">焦珂, 刘勐. 甘肃道地药材专利信息分析[J]. 甘肃医药, 2020, 39(9): 826-828.</mixed-citation></ref><ref id="hanspub.44979-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">胡静, 李科, 李爱平, 等. 当归补血汤物质基础研究进展[J]. 中草药, 2020, 51(21): 5658-5663.</mixed-citation></ref><ref id="hanspub.44979-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">沈璟, 邓海滨. 应用中医药疗法防治化疗后骨髓抑制的研究进展[J]. 当代医药论丛, 2018, 16(7): 48-51.</mixed-citation></ref><ref id="hanspub.44979-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">吴素芬, 余日跃, 周俊, 等. 析因设计与中医补气生血方剂最佳药效配伍的研究[J]. 中国实验方剂学杂志, 2011, 17(8): 153-156.</mixed-citation></ref><ref id="hanspub.44979-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hou, B.N., Liu, R., Qin, Z., et al. (2017) Oral Chinese Herbal Medicine as an Adjuvant Treatment for Chemotherapy, or Radiotherapy, Induced Myelosuppression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evidence-Based Complementray and Alternative Medicine, 2017, Article ID: 3432750.  
&lt;br&gt;https://doi.org/10.1155/2017/3432750</mixed-citation></ref><ref id="hanspub.44979-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">丁欢, 吴承杰, 潘娅岚, 等. 黄芪及当归改善化疗后骨髓抑制的分子机制研究进展[J]. 中国医药导报, 2020, 17(5): 23-26.</mixed-citation></ref><ref id="hanspub.44979-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">李杨, 郝俊杰. 基于网络药理学的当归补血汤治疗贫血的作用机制研究[J]. 大理大学学报, 2018, 3(10): 1-6.</mixed-citation></ref><ref id="hanspub.44979-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">汪变红, 张明智, 付晓瑞, 等. 化放疗骨髓抑制机制及防治研究进展[J]. 肿瘤基础与临床, 2013, 26(2): 162-165.</mixed-citation></ref><ref id="hanspub.44979-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">范奎, 代良敏, 伍振峰, 等. 放化疗所致骨髓抑制的研究进展[J]. 中华中医药杂志, 2017, 32(1): 210-214.</mixed-citation></ref><ref id="hanspub.44979-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">陈泓竹, 刘建明, 周芳, 等. 内源性物质代谢对药物代谢处置的影响及机制研究[J]. 中国临床药理学与治疗学, 2019, 24(5): 580-588.</mixed-citation></ref><ref id="hanspub.44979-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">叶慧, 郝海平. 内源性代谢物靶标发现及其在精准靶向肿瘤治疗中的应用前景[J]. 医学研究生学报, 2019, 32(5): 26-31.</mixed-citation></ref><ref id="hanspub.44979-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">张建永, 杨沙, 陈宽, 等. 基于网络药理学的理气活血滴丸治疗心血管疾病作用机制研究[J]. 中药材, 2019, 42(5): 1139-1145.</mixed-citation></ref><ref id="hanspub.44979-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">张晓囡, 张军平, 徐士欣, 等. 基于网络药理学的黄连解毒汤治疗高血压潜在机制研究[J]. 中草药, 2018, 49(24): 5865-5875.</mixed-citation></ref><ref id="hanspub.44979-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">白颖璐, 张金芳, 沙子珺, 等. 基于网络药理学和分子对接分析八味三香散治疗慢性心力衰竭的潜在分子机制[J]. 中国中药杂志, 2021, 46(10): 2392-2402.</mixed-citation></ref><ref id="hanspub.44979-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">翟志敏. IL-2对免疫激活和免疫耐受的双向调节作用[J]. 中国药理学通报, 2013, 29(3): 319-322.</mixed-citation></ref><ref id="hanspub.44979-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">梁可, 马进, 曲怡, 等. 黄芪皂苷对小鼠化疗贫血模型白介素-2、白介素-4和白介素-6的影响[J]. 中国医药导报, 2015, 12(18): 16-18.</mixed-citation></ref><ref id="hanspub.44979-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Toussaint, O., Medrano, E. and Zglinicki, T. (2000) Cellular and Molecular Mechanisms of Stress-Induced Premature Senescence (SIPS) of Human Diploid Fibroblasts and Melanocytes. Experimental Gerontology, 35, 927-945.  
&lt;br&gt;https://doi.org/10.1016/S0531-5565(00)00180-7</mixed-citation></ref><ref id="hanspub.44979-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">陈朝辉, 林贤雷, 林胜友. 中药对化疗致造血干细胞衰老信号通路干预的研究进展[J]. 上海中医药杂志, 2017, 51(2): 95-98.</mixed-citation></ref><ref id="hanspub.44979-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Monica, B., Rosanna, D., Daniela, M., et al. (2011) Prevention of Chemotherapy-Induced Anemia and Thrombocytopenia by Constant Administration of Stem Cell Factor. Clinical Cancer Research, 17, 6185-6191.  
&lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-11-1232</mixed-citation></ref><ref id="hanspub.44979-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">王晓玲, 赵舒武, 王媛媛, 等. 归补血汤对骨髓辐射损伤过程中NF-κB及bax、bcl-2表达的影响[J]. 中国老年学杂志, 2015, 35(11): 14-17.</mixed-citation></ref><ref id="hanspub.44979-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">John, N. and Eric, V. (2013) Ketone Bodies as Signaling Metabolites. Trends in Endocrinology and Metabolism, 25, 42-52. &lt;br&gt;https://doi.org/10.1016/j.tem.2013.09.002</mixed-citation></ref><ref id="hanspub.44979-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">John, N. and Eric, V. (2017) β-Hydroxybutyrate: A Signaling Metabolite. Annual Review of Nutrition, 37, 51-76.  
&lt;br&gt;https://doi.org/10.1146/annurev-nutr-071816-064916</mixed-citation></ref><ref id="hanspub.44979-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">刘喆, 李艺辉, 薛贞雅, 等. 化疗药物对骨髓基质细胞的氧化性损伤[J]. 中国实验血液学杂志, 2019, 27(3): 970-975.</mixed-citation></ref><ref id="hanspub.44979-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Wei, Q.Z. and Paul, F. (2018) Niches for Hematopoietic Stem Cells and Their Progeny. Immunity, 48, 632-648.  
&lt;br&gt;https://doi.org/10.1016/j.immuni.2018.03.024</mixed-citation></ref></ref-list></back></article>